We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Data from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) will be presented
as a late breaking clinical trial at the American College of Cardiology Scientific
Sessions 2005 March 8 in Orlando, Fla.
Durect, an emerging specialty pharmaceuticals systems company, has announced
the completion of dosing of the Phase I pharmacokinetic study for Durect's
Transdur-based sufentanil patch.
NeoRx has announced the presentation of updated data from an investigator-sponsored
Phase I Trial of STR, NeoRx's investigational bone-targeted radiotherapeutic,
in patients with advanced breast cancer.
Citing patient safety concerns and scientific findings, Amgen has confirmed
its previous decision to halt clinical trials of the experimental drug GDNF
(Glial-cell-lined-derived neurotrophic factor) for Parkinson's disease.
GenVec has received a letter from the FDA that allows the company to proceed
with the randomized, controlled portion of the Phase II clinical trial of TNFerade
in patients with locally advanced pancreatic cancer.
Kosan Biosciences has begun a multicenter Phase II clinical trial to evaluate
the safety and efficacy of KOS-862 (Epothilone D) as monotherapy for prostate
cancer.
Cephalon has announced that its Phase III studies of 150- and 250-mg daily doses
of Nuvigil in patients suffering from either excessive sleepiness associated
with narcolepsy, shift work sleep disorder (SWSD) or obstructive sleep apnea/hypopnea
syndrome (OSA/HS) show that the medication significantly improves wakefulness
and the overall clinical condition of patients as compared to placebo.
The FDA has granted final approval for Mylan's abbreviated new drug application
for citalopram hydrobromide tablets, the generic version of Forest Laboratories'
antidepressant Celexa.